Overview

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.
Phase:
PHASE3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Carboplatin
pembrolizumab
Pemetrexed